CLIFFSIDE PARK, N.J. & KURUME, Japan--(BUSINESS WIRE)--Pop Test Cortisol LLC, under the umbrella of the POP Test companies, today announced pre-clinical trials in which the company has successfully demonstrated the efficacy of a chemotherapy sensitizer for “triple negative” breast cancer. These are the most difficult to treat breast cancers, testing negative for estrogen-receptor, progesterone-receptor and her-2/neu and are resistant to chemotherapy.
